ADVA posts strongest Q1 results in company’s history
ADVA (ISIN: DE0005103006), a leading provider of open networking solutions for the delivery of cloud and mobile services, reported record financial results for Q1 2021 ended on March 31, 2021. The results have been prepared in accordance with International Financial Reporting Standards (IFRS).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210421005956/en/
Brian Protiva, CEO, ADVA (Photo: Business Wire)
Q1 2021 financial summary1
|
(in thousands of EUR) |
Q1 |
Q1 |
Change |
Q4 |
Change |
|
||||||||||||||||
|
|
2021 |
2020 |
|
2020 |
|
|
||||||||||||||||
|
|
|
|||||||||||||||||||||
|
Revenues |
144,473 |
132,686 |
8.9% |
140,572 |
2.8% |
|
||||||||||||||||
|
Pro forma gross profit |
55,345 |
42,275 |
30.9% |
54,641 |
1.3% |
|
||||||||||||||||
|
in % of revenues |
38.3% |
31.9% |
6.4pp |
38.9% |
-0.6pp |
|
||||||||||||||||
|
Pro forma operating income |
12,860 |
-1,671 |
869.6% |
14,343 |
-10.3% |
|
||||||||||||||||
|
in % of revenues |
8.9% |
-1.3% |
10.2pp |
10.2% |
-1.3pp |
|
||||||||||||||||
|
Operating income (loss) |
11,573 |
-4,038 |
386.6% |
13,085 |
-11.6% |
|
||||||||||||||||
|
Net income |
11,228 |
-7,235 |
255.2% |
13,249 |
-15.3% |
|
||||||||||||||||
|
|
||||||||||||||||||||||
|
(in thousands of EUR) |
Mar. 31 2021 |
Mar. 31 2020 |
Change |
Dec. 31 2020 |
Change |
|
||||||||||||||||
|
Cash and cash equivalents |
79,060 |
52,753 |
49.9% |
64,881 |
21.9% |
|
||||||||||||||||
|
Net debt |
10,626 |
67,705 |
-84.3% |
25,545 |
-58.4% |
|
||||||||||||||||
|
Net working capital |
125,785 |
134,219 |
-6.3% |
129,853 |
-3.1% |
|
||||||||||||||||
1 Potential difference due to rounding
Q1 2021 IFRS financial results
Revenues in Q1 2021 reached EUR 144.5 million, up by 2.8% from EUR 140.6 million in Q4 2020, also up by 8.9% compared to EUR 132.7 million in the same year-ago period, and are within the guidance corridor of between EUR 143 million and EUR 148 million. This success was particularly due to high order volume from network operators as well as private companies and governments.
Pro forma gross profit in Q1 2021 increased by 1.3%, reaching EUR 55.3 million (38.3% of revenues) compared to EUR 54.6 million (38.9% of revenues) in Q4 2020 and increased significantly by 30.9% compared to EUR 42.3 million reported in the year-ago quarter. Orders for network synchronization technology again developed positively in Q1. In addition, the customer mix contributed positively to the margin increase in the past quarter.
Pro forma operating income for Q1 2021 was EUR 12.9 million (8.9% of revenues) and decreased by 10.3% compared to EUR 14.3 million (10.2% of revenues) reported in Q4 2020. Compared to the year-ago quarter, pro forma operating income improved significantly by 869.6% from a loss of EUR 1.7 million (-1.3% of revenues). Hence the pro forma operating margin was at the top end of the guidance corridor of 7% to 9%. In addition to the higher gross profit, this substantial margin improvement is mainly due to improved operational expenditures.
Operating income for Q1 2021 of EUR 11.6 million decreased by 11.6% from EUR 13.1 million reported for Q4 2020 and significantly increased by 386.6% from a loss of EUR 4.0 million in the same year-ago quarter.
Net income reached EUR 11.2 million in Q1 2021, down by 15.3% from EUR 13.2 million in Q4 2020, and significantly up by 255.2% from a loss of EUR 7.2 million in Q1 2020.
The company’s cash and cash equivalents totaled EUR 79.1 million, representing an increase of EUR 14.2 million compared to EUR 64.9 million at the end of Q4 2020. Year-over-year cash and cash equivalents substantially increased by EUR 26.3 million from EUR 52.7 million at the end of Q1 2020. The higher cash balance is mainly the result of the improved profitability and lower capital expenditures, particularly compared to the prior-year quarter.
Consequently, net debt in Q1 2021 strongly decreased by EUR 14.9 million to EUR 10.6 million from EUR 25.5 million at the end of Q4 2020 and improved significantly by EUR 57.1 million compared to Q1 2020 (EUR 67.7 million).
Net working capital at quarter-end was EUR 125.8 million and decreased by EUR 4.1 million compared to EUR 129.9 million at the end of Q4 2020.
Management commentary
“Today we report the best Q1 in our long history as a publicly listed company. We’ve never posted higher revenues in the first quarter of a financial year, and we’ve never achieved higher profitability, generated more cash, or recorded a better order intake,” commented Brian Protiva, CEO, ADVA. “The speed of digitization in many countries has increased noticeably and we are seeing very good demand from all of our customer groups. At the same time, we are making good progress with the transformation of our business. Focus on growth markets with a higher proportion of software and services as well as more verticalization will bring our pro forma EBIT to around 10% of revenues.”
“Our transformation strategy combined with strict cost control showed the expected effects and have opened the door to sustainably higher margin potential. Net income of EUR 11.2 million is already over 50% of the result generated in 2020. With that, we have made an excellent start to the new financial year,” said Uli Dopfer, CFO, ADVA. “We were able to further increase cash and reduce net debt to EUR 10.6 million. This further underlines our strong financial position.”
Financial outlook 2021
For the fiscal year 2021, ADVA expects revenues to be in the range of EUR 580 million and EUR 610 million and a pro forma operating income of between 6.0% and 10.0% of revenues.
The company will publish its financial results for Q2 2021 on July 22, 2021.
Conference call details
ADVA will hold a conference call for analysts and investors today, April 22, 2021, to discuss the Q1 2021 results. The company’s CEO, Brian Protiva, and CFO, Uli Dopfer, will host the call at 3:00 p.m. CEST (9:00 a.m. EDT). A question and answer session will follow management presentations.
A corresponding presentation is available on ADVA’s website:
https://www.adva.com/en/about-us/investors/financial-results/conference-calls
The complete quarterly statement 3M 2021 (January – March) is available as a PDF:
https://www.adva.com/en/about-us/investors/financial-results/financial-statements
A replay of the call will be available here:
https://www.adva.com/en/about-us/investors/financial-results/conference-calls
Forward-looking statements
The economic projections and forward-looking statements contained in this document relate to future facts. Such projections and forward-looking statements are subject to risks that cannot be foreseen and that are beyond the control of ADVA. ADVA is therefore not in a position to make any representation as to the accuracy of economic projections and forward-looking statements or their impact on the financial situation of ADVA or the market in the shares of ADVA.
Use of pro forma financial information
ADVA provides consolidated pro forma financial results in this press release solely as supplemental financial information to help investors and the financial community make meaningful comparisons of ADVA’s operating results from one financial period to another. ADVA believes that these pro forma consolidated financial results are helpful because they exclude non-cash charges related to the stock option programs and amortization and impairment of goodwill and acquisition-related intangible assets, which are not reflective of the company’s operating results for the period presented. Additionally, expenses related to restructuring measures are not included. This pro forma information is not prepared in accordance with IFRS and should not be considered a substitute for the historical information presented in accordance with IFRS.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005956/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Steven Williams
t +49 89 890 66 59 18
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Blue Matter Establishes New Capabilities in Biopharma Research & Development Led by Partner, Tara Austraat-Churik13.1.2026 16:01:00 EET | Press release
Blue Matter is pleased to announce that it has established a practice area dedicated to serving clients in biopharmaceutical Research & Development (R&D). The practice is led by Tara Austraat-Churik, a Partner who joined the firm in September 2025. Tara Austraat-Churik has been serving life science clients for more than 20 years. Her areas of expertise include strategy development and implementation, operating model and organizational design, and process optimization in R&D and Medical Affairs. Prior to joining Blue Matter, she served as Managing Director in R&D, Health, Science, and Wellness at EY. She has a robust background in consulting, which also includes roles at Booz Allen Hamilton, Navitas, WPP, and IBM. She holds a BA and MA from the University of Notre Dame and an MSc in Translational Medicine from the University of Edinburgh. The R&D practice, according to Austraat-Churik, exists to help biopharma companies simplify and accelerate the pathway to market. She adds, “R&D organ
Wasabi Raises $70M in New Equity to Power the Next Era of Data Infrastructure13.1.2026 16:00:00 EET | Press release
Wasabi Technologies, the Hot Cloud Storage company, today announced a $70 million equity funding round led by L2 Point Management with participation from Pure Storage and existing investors including Fidelity Management & Research Company. The new round values Wasabi at $1.8 billion and brings the company’s total funding to over $600 million. The capital will be used to accelerate Wasabi’s expansion into AI infrastructure, broaden its global footprint, and enhance its product portfolio to meet the growing data demands of enterprises and AI developers worldwide. “We’re ushering in the next generation of cloud storage, powering data-intensive workloads like generative AI and autonomous systems,” said David Friend, co-founder and CEO of Wasabi Technologies. “This funding underscores Wasabi’s strong market position and continued growth as enterprises and AI developers alike seek a better, more predictable alternative to the hyperscalers.” Wasabi disrupted the cloud storage model in 2017 wi
Armis Secures Italy’s Primary Public Healthcare Provider for the City of Naples as Cyber Threats Increase13.1.2026 15:00:00 EET | Press release
Armis, the cyber exposure management & security company, today announced that ASL Napoli 1 Centro, Italy’s primary public healthcare provider for the City of Naples, is securing its attack surface using Armis Centrix™, the Armis Cyber Exposure Management Platform. Prior to working with Armis, ASL Napoli 1 Centro did not have the tools or capabilities to monitor physical and virtual assets in real time, which posed a challenge for its security and compliance. Armis Centrix™ was deployed with a clear goal: to provide ASL Napoli 1 Centro with a comprehensive, real-time view of its connected biomedical inventory and the associated risks to the overall environment. “Time-to-value was practically immediate; Armis began delivering valuable information as soon as the system was activated and connected to our internal network,” said Fulvio Paone, Director of the ICT and Digital Transformation Unit at ASL Napoli 1 Centro. “Armis has given us visibility into a critical area. This isn’t just about
Opengear Introduces CM8000 and OM1300: Two New Paths to Network Resilience as Outages Surge13.1.2026 15:00:00 EET | Press release
Opengear, a Digi International company (NASDAQ, DGII), today announced two new additions to its Network Resilience Platform: the CM8000 Series and the OM1300 Series. These next generation devices deliver compact, flexible, and automation-ready out-of-band infrastructure designed for a time when outages are increasing and distributed sites continue to scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113807672/en/ Opengear Introduces CM8000 and OM1300: Two New Paths to Network Resilience as Outages Surge According to Opengear research, 84 percent of CIOs and CISOs have experienced a rise in outages over the past two years. The CM8000 Series and OM1300 Series were purpose-built to ensure that IT teams maintain access and control even when the production network is unavailable. The two series provide complementary approaches: CM8000 Series A serial-first recovery platform with integrated power control for core branches,
GARDP and Debiopharm Partner to Advance Development of Novel Gonorrhea Drug13.1.2026 15:00:00 EET | Press release
The GARDP Foundation (known as GARDP) and the privately-owned, global biopharmaceutical company Debiopharm today announced that they have entered into a collaboration and license agreement to pursue the development of Debio1453, a novel, first-in-class antibiotic targeting Neisseria gonorrhoeae. With 82 million new cases each year, and the continued spread of multidrug-resistant N. gonorrhoeae strains, gonorrhea represents a global health crisis. This new partnership will help ensure that gonorrhea continues to be a treatable disease and will alleviate the risk of the emergence of future resistance, by ensuring that the antibiotic pipeline continues to be replenished. Gonorrhea caused by N. gonorrhoeae is currently in danger of becoming untreatable because of antimicrobial resistance (AMR). Having developed resistance to almost all antibiotics used to treat it, only one last recommended treatment, ceftriaxone, remains effective, and now we are seeing a growing number of cases that are
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
